Guidelines for the performance of CD4+ T-cell determinations in persons with human immunodeficiency virus infection
Advanced Search
Select up to three search categories and corresponding keywords using the fields to the right. Refer to the Help section for more detailed instructions.
 
 
i

Superseded

This Document Has Been Replaced By:

i

Retired

This Document Has Been Retired

i

Up-to-date Information

This is the latest update:

Guidelines for the performance of CD4+ T-cell determinations in persons with human immunodeficiency virus infection
  • Published Date:

    May 8, 1992

  • Status:
    superseded
  • Source:
    MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports / Centers for Disease Control. 1992; 41(RR-8):1-17.
  • Language:
    English
Filetype[HTM]


This is an HTML document so it cannot be previewed.
To open, click the "View" button.
Details:
  • Supporting Files:
    No Additional Files
No Related Documents.

You May Also Like:

  1. Filetype[PDF - 317.63 KB]
    Personal Author:
    Nicholson, Janet K. A., 1948-; McDougal, J. Steven; Hearn, Thomas L.; Collins, Carlyn L.; Velleca, Wallis M.; Jones, Wanda K.; Gerber, A. Russell;
    Corporate Authors:
    Centers for Disease Control and Prevention (U.S.). Public Health Practice Program Office.. National Center for Infectious Diseases (U.S.). National Center for Prevention Services (U.S.).
    Published Date:
    March 4, 1994
    Source:
    MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports / Centers for Disease Control. 1994; 43(RR-3):1-21.
    Series:
    DHEW publication ; no. (NIOSH) 2004-124
    MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports ; v. 43, no. RR-3
    Description:
    The Food and Drug Administration (FDA) has recommended that all donated blood be screened for antibodies to human immunodeficiency virus type 2 (HIV-2) beginning no later than June 1, 1992. This article provides CDC recommendations for the DIAGNOSIS ...
    File Type:
    Filetype[PDF - 317.63 KB]
  2. Filetype[PDF - 311.48 KB]
    Corporate Authors:
    Centers for Disease Control and Prevention (U.S.)
    Published Date:
    January 10, 1997
    Source:
    MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports / Centers for Disease Control. 1997; 46(RR-2):1-29.
    Description:
    Human immunodeficiency virus counseling and testing services (HIV-CTS) have been recommended by CDC since 1985, when serologic tests became available to detect antibodies to HIV (1,2). In August 1987, CDC published the Public Health Service Guideline...
    File Type:
    Filetype[PDF - 311.48 KB]
  3. Filetype[PDF - 1.05 MB]
    Personal Author:
    Doitsh, Gilad; Greene, Warner C.;
    Published Date:
    Mar 09 2016
    Source:
    Cell Host Microbe. 19(3):280-291.
    Description:
    Although the replicative life cycle of HIV within CD4 T cells is understood in molecular detail, less is known about how this human retrovirus promotes the loss of CD4 T lymphocytes. It is this cell death process that drives clinical progression to a...
    File Type:
    Filetype[PDF - 1.05 MB]
  4. Filetype[PDF - 358.35 KB]
    Corporate Authors:
    U.S. Public Health Service Task Force on the Use of Zidovudine to Reduce Perinatal Transmission of Human Immunodeficiency Virus.
    Published Date:
    August 5, 1994
    Source:
    MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports / Centers for Disease Control. 1994; 43(RR-11):1-20.
    Description:
    These recommendations update the interim guidelines (1) developed by the U.S. Public Health Service for the use of zidovudine (ZDV) to reduce the risk for perinatal transmission of human immunodeficiency virus (HIV) infection. The recently reported r...
    File Type:
    Filetype[PDF - 358.35 KB]
  5. Filetype[PDF - 103.31 KB]
    Personal Author:
    Thomas, Paul G.; Keating, Rachael; Hulse-Post, Diane J.; Doherty, Peter C.;
    Published Date:
    Jan 2006
    Source:
    Emerg Infect Dis. 12(1):48-54.
    Description:
    Current vaccine strategies against influenza focus on generating robust antibody responses. Because of the high degree of antigenic drift among circulating influenza strains over the course of a year, vaccine strains must be reformulated specifically...
    File Type:
    Filetype[PDF - 103.31 KB]